<DOC>
	<DOCNO>NCT01152346</DOCNO>
	<brief_summary>The purpose study determine bioavailability Azacitidine Injection relative Vidaza® MDS patient fast condition . The data evaluate statistically determine product meet bioequivalence criterion .</brief_summary>
	<brief_title>Bioequivalence Study Azacitidine Injection Myelodysplastic Syndrome ( MDS ) Patients</brief_title>
	<detailed_description>This study open label , multi-center randomized , single dose , two-treatment , two-period , two-sequence , two-way cross-over , relative bioavailability study Azacitidine Injection suspension use manufacture Bioniche Pharma USA LLC compare Vidaza® manufacture Celgene Corporation MDS patient fast condition . Patients stable 75 mg/m2 dose Vidaza randomize study drug sequence Azacitidine C1D1/ Vidaza® C2D1 Vidaza® C1D1 / Azacitidine C2D1 . Randomization 2:2 ratio . Thirty-six ( 36 ) patient enrol ensure 28 evaluable patient . Patients blind treatment assignment . After randomization , fast patient receive 1 dose assign study drug ( either Azacitidine Injection Vidaza® ) subcutaneously dose 75 mg/m2 C1D1 . On Days 2-7 , receive normal Vidaza® treatment . Following 21 day rest period , patient cross receive alternate treatment C2D1 follow normal Vidaza® ) treatment Cycle 2 Days 2-7 . The Final Patient Visit conduct 7 day follow last dose Vidaza® . The total duration study patient 56 day include Screening period Post Study Visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Male female patient age &gt; 18 year . Patients Myelodysplastic Syndrome ( MDS ) place Vidaza® accord Marketing Authorization issue country clinical study conduct ( i.e. , US , patient follow FrenchAmericanBritish ( FAB ) subtypes : Refractory Anemia ( RA ) , Refractory Anemia Ringed Sideroblasts ( RARS ) , ( accompany neutropenia thrombocytopenia require transfusion ) , Refractory Anemia Excess Blasts ( RAEB ) , Refractory Anemia Excess Blasts Transformation ( RAEBT ) Chronic Myelomonocytic Leukemia ( CMMoL ) ; France , subject eligible hematopoietic stem cell transplantation : intermediate 2 highrisk myelodysplastic syndrome accord International Prognostic Scoring System ( IPSS ) chronic myelomonocytic leukemia ( CMML ) 1029 % marrow blast without myeloproliferative disorder ) currently receive Vidaza 75 mg/m2 ; Patient life expectancy &gt; 6 month . Patients performance status 0 2 per ECOG Scale . Patients Total Bilirubin &lt; 1.5 x ULN ; ALT/AST &lt; 2 x ULN , Serum Creatinine &lt; 1.5 ULN , Serum Bicarbonate &gt; 19 mEq/L . Patients sign Informed Consent Form . Patients history alcoholism drug addiction ( past 2 year ) Patients severe hepatic impairment , impaired renal function , condition Investigator 's opinion would contraindicate would interfere absorption study drug . Patients whose clinical laboratory test value outside reference range may retested discretion Investigator . If clinical value outside range retesting , patient eligible participate study unless Investigator deem result significant . Patients active malignancy within past 5 year except cervical cancer situ , situ carcinoma bladder nonmelanoma carcinoma skin . Patients history allergic response class drug test . Patients hypersensitivity Mannitol . Patients donate blood and/or plasma least thirty ( 30 ) day prior first dose study drug . Patients transfusion blood product least 7 day prior . Patients take investigational drug within thirty ( 30 ) day prior first dose study . Female patient pregnant , breastfeeding , likely become pregnant study . Female patient child bear potential instruct either abstain sexual intercourse use acceptable method birth control course study 3 month afterward . Male patient female partner also use acceptable method birth control . Any patient Investigator believe good candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Azacitidine</keyword>
</DOC>